Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 269 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatic Failure Clear all

Conditions: Ventilation, ARDS, Respiratory Failure, Mechanical Ventilation, Ventilator-induced Lung Injury (VILI), Quality Improvement, Ventilator Associated Events
Interventions: RKP Monitoring Software; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 100 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin, placebo; Drug
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Congestive Heart Failure
Interventions: Heart Self Care Tracker, Heart Care Self Tracker; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Aurora, California • Fresno, California + 28 more

Conditions: Acute Hepatitis, Chronic Hepatitis
Interventions: ELAD plus standard of care treatment, Standard of care treatment; Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 19 Years to 69 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: La Jolla, California • San Francisco, California • Chicago, Illinois + 3 more

Conditions: End Stage Liver Disease
Interventions: Advance Care Planning Video Decision Support Tool, Verbal Narrative; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Cirrhosis, Hemophilia, Hemophilia A, Hemophilia B, Liver Transplant Disorder, Liver Failure, Coagulation Factor Deficiency
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Minimal Hepatic Encephalopathy
Interventions: Lactobacillus GG, Placebo; Biological
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatic Encephalopathy
Interventions: Home Recordings, In-patient Recordings, Same-Day Study Visit - Regular Appointment, Same-Day Study Visit - Procedure, Phone Call Follow-up Visits; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cirrhosis, Hepatic Encephalopathy
Interventions: Placebo, VE303, oral vancomycin; Drug
Lead sponsor: Patricia Bloom; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: End Stage Liver Disease, Hepatitis C
Interventions: Treatment with Direct Acting Antiviral tablet; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Liver Cancer, Liver Metastases
Interventions: Not listed
Lead sponsor: Maastricht University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • Cleveland, Ohio

Conditions: End Stage Liver DIsease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Virus Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatic Encephalopathy, Cirrhosis, Liver
Interventions: RBX7455, Placebo; Biological
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Jefferson, Louisiana

Conditions: Acute Alcoholic Hepatitis
Interventions: ELAD treatment, Standard of care (Control); Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more

Conditions: Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
Interventions: MARS, Standard Medical Therapy; Device · Drug
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 6
States / cities: Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more

Conditions: Hepatic Insufficiency
Interventions: Alisporivir; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more

Conditions: Hepatic Insufficiency
Interventions: BMS-790052; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Anaheim, California • Orlando, Florida

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Hepatic Veno-Occlusive Disease
Interventions: Defibrotide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 22
States / cities: Duarte, California • Palo Alto, California • Denver, Colorado + 19 more

Conditions: Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C, Liver Cirrhosis
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years and older
Enrollment: 1,871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Healthy, Hepatic Insufficiency
Interventions: BI 685509, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Respiratory Knowledge Portal Computer and Phone Application to Improve Quality of Mechanical Ventilation by Reducing the Number of Ventilator Associated Events, Injury Created by the Ventilator and Unsafe Setting of Alarms.

Rifaximin in Minimal Hepatic Encephalopathy

Heart Failure Patient Self-Management Web Portal Pilot Study

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease

Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy

Speech in Hepatic Encephalopathy (HE)

VE303 for Treatment of Hepatic Encephalopathy (HE)

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

Disparities Among Liver Transplant Patients

Collection of Liver Tissue for Virologic Studies

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Adult-to-Adult Living Donor Transplant Cohort Study

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems